Welling­ton, HBM lead €24M round as Adrenomed preps sep­tic shock treat­ment for hu­man test­ing

A low-pro­file biotech work­ing in the out­skirts of Berlin has se­cured €24 mil­lion ($27 mil­lion) to make a dent in the no­to­ri­ous­ly high mor­tal­i­ty rate of sep­tic shock, with ma­jor back­ing from sto­ried Eu­ro­pean firms Welling­ton Part­ners and HBM Health­care In­vest­ments.

While the round is tech­ni­cal­ly a Se­ries D, it marks the first “ac­tu­al in­vest­ment” for the 12-per­son crew at Adrenomed, which has been run­ning its op­er­a­tion so far us­ing in­ter­nal fund­ing since its cre­ation by for­mer ex­ecs of the di­ag­nos­tics firm BRAHMS — best known for its flag­ship sep­sis prod­uct — in 2009.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER